Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue 1, 2009, Pages 10-13

  Tabarsi, Payam ^a   Baghaei, Parvaneh ^a   Jalali, Sara ^a   Farnia, Parisa ^a   Chitsaz, Ehsan ^a   Mirsaeidi, Mehdi ^a   Kazempour, Mehdi ^a   Mansouri, Davoud ^a   Masjedi, Mohammad ^a   Velayati, Ali ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AFGHANISTAN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; HUMAN; IRAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AFGHANISTAN; AMIKACIN; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; IRAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 58049211945     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540802298079     Document Type: Article

References (22)

1. Mukherjee, JS, Rich, ML, Socci, AR, Joseph, JK, Viru, FA Shin, SS et al. (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet, 363, pp. 474-481.
2. Seaworth, BJ (2002) Multidrug-resistant tuberculosis. Infect Dis Clin North Am, 16, pp. 73-105.
3. Geerligs, WA, van Altena, R., de Lange, WCM, van Soolingen, D. and van der Werf, TS (2000) Multidrug-resistant tuberculosis: Long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis, 4, pp. 758-764.
4. Telzak, EE, Sepkowitz, K., Alpert, P., Mannheimer, S., Medard, F. El-sadr, W. et al. (1995) Multidrug-resistant tuberculosis inpatients without HIV infection. N Engl J Med, 333, pp. 907-911.
5. Escudero, E., Pena, JM, Alvarez-Sala, R., Vazquez, JJ and Ortega, A. (2006) Multidrug-resistant tuberculosis without HIV infection: Success with individualized therapy. Int J Tuberc Lung Dis, 10, pp. 409-414.
6. Centers for Disease Control and Prevention (CDC) (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep, 55, pp. 301-305.
7. Mirsaeidi, SM, Tabarsi, P., Khoshnood, K., Pooramiri, MV, Rowhani-Rahbar, A. Mansoori, SD et al. (2005) Treatment of multidrug-resistant tuberculosis (MDR-TB) in Iran. Int J Infect Dis, 9, pp. 317-322.
8. Masjedi, MR, Farnia, P., Sorooch, S., Pooramiri, MV, Mansoori, SD Zarifi, AZ et al. (2006) Extensively drug-resistant tuberculosis: 2 y of surveillance in Iran. CID, 43, pp. 841-847.
9. Caminero, JA, World Health Organization, American Thoracic Society and British Thoracic Society (2006) Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int J Tuberc Lung Dis, 10, pp. 829-837.
10. Caminero, JA (2005) Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J, 25, pp. 928-936.
11. Kim, SJ (2005) Drug susceptibility testing in tuberculosis: Methods and reliability of results. Eur Respir J, 25, pp. 564-569.
12. Iseman, MD (1993) Treatment of multidrug-resistant tuberculosis. N Engl J Med, 329, pp. 784-791.
13. Chiang, CY, Enarson, DA, Yu, MC, Bai, KJ, Huang, RM Hsu, CJ et al. (2006) Outcome of pulmonary multidrug-resistant tuberculosis: A 6-y follow-up study. Eur Respir J, 28, pp. 980-985.
14. World Health Organization (2006) Guidelines for the programmatic management of drug resistant tuberculosis, WHO, Geneva, Switzerland
15. van Deun, A., Salim, MA, Das, AP, Bastian, I. and Portaels, F. (2004) Results of a standardized regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis, 8, pp. 560-567.
16. Suarez, PG, Floyd, K., Portocarrero, J., Alarcon, E., Rapiti, E. Ramos, G. et al. (2002) Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: A national cohort study in Peru. Lancet, 359, pp. 1980-1989.
17. Tahaoglu, K., Torun, T., Sevim, T., Atac, G., Kalyoncu, A. Karasulu, L. et al. (2001) The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med, 345, pp. 170-174.
18. Leimane, V., Riekstina, V., Holtz, T., Zarovska, E., Skripconoka, V. Thorpe, LE et al. (2005) Clinical outcome of individualized treatment of multidrug resistant tuberculosis in Latvia: An retrospective cohort study. Lancet, 365, pp. 318-326.
19. Nathanson, E., Lambregts-van Weezenbeek, C, Rich, ML, Gupta, R., Bayona, J. Blondal, K. et al. (2006) Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis, 12, pp. 1389-1397.
20. Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J. Alcantara, F. et al. (2003) Community based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med, 348, pp. 119-128.
21. Bedi, RS (2003) Saving quinolones for tuberculosis. J Assoc Physicians India, 51, pp. 933-934.
22. Agarwal, A. (2003) TB should be diagnosed before using a fluoroquinolone. Br Med J, 327, pp. 164-165.